

Efficacy of molecular techniques in Down syndrome analysis for future diagnosis

Forough Shabannejadian

Department of Genetic Engineering
Islamic Azad University - Ahvaz Branch
Ahvaz, Iran

foroughshabannejadian@gmail.com

Abstract— Down syndrome (DS) is a genetic disorder appeared due to the presence of trisomy in chromosome 21 in the G-group of the acrocentric region. DS is also known as non-Mendelian inheritance, due to the lack of Mendel's laws. The disorder in children is identified through clinical symptoms and chromosomal analysis and till now there are no biochemical and molecular analyses. Presently, whole exome sequencing (WES) has largely contributed in identifying the new diseasecausing genes and represented a significant breakthrough in the field of human genetics and this technique uses high throughput sequencing technologies to determine the arrangement of DNA base pairs specifying the protein coding regions of an individual's genome. Apart from this next generation sequencing and whole genome sequencing also contribute for identifying the disease marker. From this review, the suggestion was to perform the WES in DS children to identify the marker region.

Keywords: Downs syndrome, Exome sequencing, Chromosomal analysis, Genes, Genetics.

I. INTRODUCTION

Down syndrome (DS) is an autosomal genetic disorder that causes Intellectual disability and increased risk of organic disorders caused by the trisomy 21 (21q22 region), appearance of additional chromosome leading to birth defects (Mendioroz et al., 2015). Chromosomal aneuploidy is one of the main causes of developing trisomy 21 (Kamhieh-Milz et al., 2014). DS affects 1 in 1000 in live born children throughout the globe. Earlier studies have reported the risk of DS when the maternal age is greater than 40 years, and increased age of the maternal grandmother may increase the risk of DS. Maternal age plays an important role in the frequency of DS (Ellaithi et al., 2008). The phenotypic characters are brachycephaly, flat

facies, upward slanting palpebral fissures, epicanthus, and low-set round ears with abnormal folds, epicanthus, and unique transverse palmar crease, among others. Diagnosis is purely based on clinical features, and cytogenetic analysis (Garduno-Zarazu'a et al., 2013). The clinical symptoms of DS are protruding tongue, small head, poor muscle tone (hypotonia), short height, flattened facial features, short hands and fingers (Patil et al., 2014). The initial identification of DS was based upon the clinical symptoms followed by karyotyping and fluorescent in situ hybridization analysis. There are no biochemical, histological, pathological and molecular tests to diagnose the DS. Unfortunately, the diagnosis of DS was performed with the chromosomal analysis. Cytogenetics is the time taking process (>72 h) for the identification of the diagnosis. The development of extra chromosome is due to the error in cell division (chromosomal non-disjunction in meiosis 1). Trisomy 21 is an error in meiosis, i.e. failure of normal chromosomal pairing or premature unpairing and has a recurrence risk of about 1 in 100. The appearance of trisomy 21 is due to the improper development of egg/sperm cells during meiosis and subsidizes extra chromosome.

II. HISTORY

Escorel was the first person to describe the Down syndrome (DS) in children in 1838 (Weijerman, 2011). Later on, the DS was discovered by British physician Prof. John Langdon Haydon Down (John Down) as a mental disorder in 1866. From his research, he analyzed the children with DS has common physical characteristics, similar to Mongolian race and termed the disease as Mongolian Idiocy or Mongolism and patients were denoted as Mongoloids. Later on Lejeune, Turpin and Gautier identified the third